Wall Street Zen Upgrades Pulmonx (NASDAQ:LUNG) to Hold

Pulmonx (NASDAQ:LUNG) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other equities research analysts have also recently weighed in on the stock. Piper Sandler cut shares of Pulmonx from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $9.00 to $2.50 in a research report on Thursday, July 31st. Stifel Nicolaus cut their price target on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Wednesday, October 8th. Wells Fargo & Company dropped their price objective on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Finally, Lake Street Capital cut their target price on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.81.

Pulmonx Price Performance

Shares of LUNG opened at $1.36 on Friday. The business has a 50-day moving average of $1.70 and a 200-day moving average of $2.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The company has a market capitalization of $56.10 million, a price-to-earnings ratio of -0.96 and a beta of 0.44. Pulmonx has a 1 year low of $1.36 and a 1 year high of $9.37.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, November 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%.The business had revenue of $21.50 million for the quarter, compared to analysts’ expectations of $20.78 million. Pulmonx has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Pulmonx will post -1.55 earnings per share for the current year.

Institutional Trading of Pulmonx

Several large investors have recently made changes to their positions in the company. Legato Capital Management LLC bought a new stake in Pulmonx in the 1st quarter valued at about $606,000. Essex Investment Management Co. LLC acquired a new stake in Pulmonx in the first quarter valued at approximately $2,041,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Pulmonx by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company’s stock valued at $2,160,000 after acquiring an additional 5,414 shares in the last quarter. Deutsche Bank AG raised its position in shares of Pulmonx by 4.2% during the first quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock worth $7,720,000 after purchasing an additional 46,116 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Pulmonx by 97.3% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,610 shares of the company’s stock worth $1,115,000 after purchasing an additional 81,669 shares in the last quarter. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.